H.C. Wainwright analyst Ananda Ghosh raised the firm’s price target on Inventiva (IVA) to $24 from $20 and keeps a Buy rating on the shares. If NATIV3 confirms Phase 2b results, lanifibranor could become “the oral backbone of MASH therapy,” says the analyst, who says that Inventiva’s analyst day reinforced lanifibranor’s differentiated positioning as the only oral, once daily pan PPAR agonist in late-stage development for MASH.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IVA:
- 3 Best Stocks to Buy Now, 10/02/2025, According to Top Analysts
- Inventiva’s Strategic Focus and Financial Stability Drive Buy Rating Amid Promising Phase 3 Trial Progress
- Inventiva management to meet with Piper Sandler
- Inventiva Appoints Andrew Obenshain as CEO to Drive U.S. Market Expansion
- Inventiva SA Reports Progress and Challenges in 2025